AVLN (Avalyn Pharma) Shares Outstanding (EOP): 41.81 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma Shares Outstanding (EOP)?

Avalyn Pharma AVLN -1.01% 11 Shares Outstanding (EOP) is 41.81 Mil as of Dec. 2025. GuruFocus rates AVLN with a GF Score™ of 11/100.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Avalyn Pharma's shares outstanding for the quarter that ended in Dec. 2025 was 41.81 Mil.

Avalyn Pharma's quarterly shares outstanding stayed the same from Dec. 2024 (41.81 Mil) to Dec. 2025 (41.81 Mil).

Avalyn Pharma's annual shares outstanding stayed the same from Dec. 2024 (41.81 Mil) to Dec. 2025 (41.81 Mil).


Avalyn Pharma  (NAS:AVLN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Avalyn Pharma Shares Outstanding (EOP) Related Terms


Avalyn Pharma Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Shares Outstanding (EOP) Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Shares Outstanding (EOP)
41.81 41.81

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
Shares Outstanding (EOP) 41.81 41.81

AVLN vs TRAX, IMTX, ARDX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Avalyn Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalyn Pharma Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Avalyn Pharma's Shares Outstanding (EOP) falls into.


AVLN
11GF Score
Avalyn Pharma Inc AVLN
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 41.81 Mil mean?
Avalyn Pharma (AVLN) has a Shares Outstanding (EOP) of 41.81 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Avalyn Pharma and its competitors.
Is Avalyn Pharma's Shares Outstanding (EOP) too high?
Avalyn Pharma's current Shares Outstanding (EOP) is 41.81 Mil. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Shares Outstanding (EOP) compare to TRAX and IMTX?
Avalyn Pharma's Shares Outstanding (EOP) of 41.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current Shares Outstanding (EOP) is 41.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Shares Outstanding (EOP) of 41.81 Mil. The current Shares Outstanding (EOP) is 41.81 Mil. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Shares Outstanding (EOP) is 41.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price